LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Strona główna・Stock List・MannKind Corp

MannKind Corp

Closed

SectorHealthcare

3.76 3.3

Buy Sell

Overview

Share price change

24h

Current

Min

3.51

Max

3.92

Key metrics
By Trading Economics
Income	-671K -17M
Sales	-22M 90M
P/E Sector Avg	140.5 50.102
EPS	-0.02
Profit margin	-18.431
Employees	591
EBITDA	5.9M 3.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+109.62% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	177M 1B
Previous open	0.46
Previous close	3.76

News Sentiment

By Acuity

28%

72%

73 / 344 Ranking in Healthcare

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 maj 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 maj 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 maj 2026, 20:53 UTC

Earnings

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 maj 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 maj 2026, 20:11 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 maj 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 maj 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 maj 2026, 19:05 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 maj 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 maj 2026, 18:12 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 maj 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 maj 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 maj 2026, 17:55 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 maj 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 maj 2026, 17:00 UTC

Earnings

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 maj 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 maj 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 maj 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

29 maj 2026, 15:55 UTC

Market Talk

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 maj 2026, 15:50 UTC

Acquisitions, Mergers, Takeovers

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 maj 2026, 15:50 UTC

Acquisitions, Mergers, Takeovers

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 maj 2026, 15:40 UTC

Market Talk

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 maj 2026, 15:20 UTC

Market Talk

Canada's Economy Not Looking All That Bright -- Market Talk

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

109.62% upside

12 Months Forecast

Average 7.63 USD 109.62%

High 10 USD

Low 4.75 USD

Based on 6 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Sentiment

By Acuity

73 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.